FDA Approves Lilly's Foundayo Weight-Loss Pill
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly's Foundayo (orforglipron) received FDA approval on Wednesday, becoming the second oral GLP-1 weight-loss drug on the US market after Novo Nordisk's Wegovy pill, which was approved in December.
- Foundayo can be taken at any time of day with or without food, unlike Wegovy's pill, which must be taken first thing in the morning on an empty stomach.
- The starting dose is projected to cost about $149/month without insurance, with higher strengths reaching up to $349/month — pricing that matches Wegovy's pill rather than undercutting it.
- David A. Ricks, Eli Lilly's chair and CEO, said fewer than 1 in 10 Americans who could benefit from a GLP-1 are currently taking one, citing access, stigma, perceived complexity, and beliefs about condition severity as barriers.
- Foundayo will begin shipping Monday through Lilly's direct-to-consumer service LillyDirect, with pharmacy and telehealth availability to follow.
- The approval came through a federal program designed to fast-track medications deemed of national importance, allowing Foundayo to reach market roughly three months after Wegovy's pill and intensifying the two-company GLP-1 rivalry.
- A Trump administration proposal could expand Medicare coverage to certain patients as early as this summer, with copayments potentially as low as $50/month.
Why it matters: Foundayo enters a market where fewer than 1 in 10 eligible Americans currently take a GLP-1, per Lilly's own CEO. Its flexible dosing and direct-to-consumer shipping could lower barriers for the needle-averse, but at $149–$349/month it matches Wegovy's pill rather than undercuts it — meaning the Trump administration's pending Medicare expansion is the real affordability lever for the millions who can't pay out of pocket.
Ask SkimNews
